(Q39579081)

13 September 2017

1 reference

title

HMG CoA reductase inhibitors. Current clinical experience (English)

1 reference

13 September 2017

Walker JF

1

1 reference

13 September 2017

1 January 1988

1 reference

13 September 2017

1 reference

13 September 2017

36 Suppl 3

1 reference

13 September 2017

83-86

1 reference

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

13 September 2017

1 reference

12 December 2020

New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

1 reference

12 December 2020

Probability of Middle-Aged Men Developing Coronary Heart Disease in Five Years

1 reference

12 December 2020

Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Cataracts produced by triparanol. (MER-29).

1 reference

12 December 2020

EFFECTS OF TRIPARANOL (MER-29) ON CHOLESTEROL BIOSYNTHESIS AND ON BLOOD STEROL LEVELS IN MAN

1 reference

12 December 2020

Clofibrate-lnduced acute muscular syndrome

1 reference

12 December 2020

10.2165/00003495-198800363-00017

Identifiers

DOI

0 references

PubMed ID

3076126

1 reference

PubMed ID

3076126